Summary
Conclusion
the dossier summarised in one paragraphThe computed 12-month bankruptcy probability of African Bio Developments is 4.7% (elevated). The 2024 annual accounts show negative equity (€-34k) and a net result of €-5k. Equity is shrinking by ~27.6% per year across the filed fiscal years. Its solvency ranks better than 5% of 37 sector peers (fiscal year 2024). The company has been active since 2020 and the Belgian State Gazette contains no insolvency or warning signals.
Based on the State Gazette, CBE and 3 annual accounts.
Bankruptcy probability (12 mo)
Checked model v1 · free for everyoneStatistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Trust signals
3 signalsAdministrative Flags
0 eventsFinancials
Annual accounts & ratios
Source: NBB · 2024How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | -1537.0% | 30.0% | |
| Net result | €-5k | €7k | |
| Equity | €-34k | €28k | |
| Gross operating margin | €-9k | €31k | |
| Total assets | €2k | €108k |
| Fiscal year | 2024 |
|---|---|
| Revenue | - |
| EBITDA | - |
| Net profit | €-5k |
| Cash flow | - |
| Staff costs | - |
| Income taxes | €-5k |
| Dividends | - |
| Total assets | €2k |
| Equity | €-34k |
| Debt | €36k |
| of which ≤ 1y | €35k |
| of which > 1y | - |
| Working capital | €-33k |
| Employees (FTE) | - |
| 2024 | |
|---|---|
| Current ratio | 0.06 |
| Quick ratio | 0.06 |
| Working capital ratio | -1493.6% |
| Solvency | -1537.0% |
| Debt / equity | -1.07 |
| Long-term debt ratio | - |
| Interest coverage | - |
| Gross margin | - |
| Net margin | - |
| ROA | -206.5% |
| ROE | 13.4% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
| Line item | Code | 2024 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €2k |
| Current assets | 29/58 | €2k |
| Amounts receivable within one year | 40/41 | €2k |
| Cash & bank | 54/58 | €659 |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €2k |
| Equity | 10/15 | €-34k |
| Contributions / capital | 10/11 | €5k |
| Accumulated profits (losses) | 14 | €-39k |
| Amounts payable | 17/49 | €36k |
| Amounts payable within one year | 42/48 | €35k |
| Trade debts payable within one year | 44 | €6k |
| Income statement | ||
| Gross operating margin | 9900 | €-9k |
| Operating result | 9901 | €-9k |
| Financial charges | 65 | €992 |
| Result before taxes | 9903 | €-10k |
| Income taxes | 67/77 | €-5k |
| Net result for the period | 9904 | €-5k |
| Result to be appropriated | 9905 | €-5k |
Health barometer
FY 2024 · computedUnlock the full score breakdown, per-year score history and the indicative credit limit with Plus.
See plans →Structure & network
Locations & real estate
Establishment units
1 locationReal-estate footprint
Source: CBE × cadastre · address linkingParcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 11052C0585/00T002 | Flanders | 1.0 ha | 1 · 2,288 m² | 14.7 m · 4 fl. |
Analysis
Snowflake analysis
financial profile on 5 axesMixed profile: strong on stability, weaker on health.
Ask AI about this company
Checked AISoon: ask questions about this dossier, risks, curator, sector comparison, answered from the official data on this page.
AI due-diligence brief
Checked AIGenerate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
Credit advice
verdict per customer and amountSimilar
Similar companies
Same sector, nearest firstCompany registry
Company registry (CBE)
Crossroads Bank| Legal nameNL | African Bio Developments |